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Brain tumors are typically resistant to conventional chemothera-
peutics, most of which initiate apoptosis upstream of mitochon-
drial cytochrome c release. In this study, we demonstrate that
directly activating apoptosis downstream of the mitochondria,
with cytosolic cytochrome c, kills brain tumor cells but not normal
brain tissue. Specifically, cytosolic cytochrome c is sufficient to
induce apoptosis in glioblastoma and medulloblastoma cell lines. In
contrast, primary neurons from the cerebellum and cortex are
remarkably resistant to cytosolic cytochrome c. Importantly, tumor
tissue from mouse models of both high-grade astrocytoma and
medulloblastoma display hypersensitivity to cytochrome c when
compared with surrounding brain tissue. This differential sensitiv-
ity to cytochrome c is attributed to high Apaf-1 levels in the tumor
tissue compared with low Apaf-1 levels in the adjacent brain tissue.
These differences in Apaf-1 abundance correlate with differences
in the levels of E2F1, a previously identified activator of Apaf-1
transcription. ChIP assays reveal that E2F1 binds the Apaf-1 pro-
moter specifically in tumor tissue, suggesting that E2F1 contributes
to the expression of Apaf-1 in brain tumors. Together, these results
demonstrate an unexpected sensitivity of brain tumors to postmi-
tochondrial induction of apoptosis. Moreover, they raise the pos-
sibility that this phenomenon could be exploited therapeutically to
selectively kill brain cancer cells while sparing the surrounding
brain parenchyma.
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Primary brain tumors arise from cells intrinsic to the brain andintracranial cavity. Although these tumors account for only
a small percentage of cancers, they cause a disproportionate
share of cancer-related morbidity and mortality (1). Despite
resection in conjunction with chemoradiation, the 5-year sur-
vival rate for glioblastoma, the most common histologic subtype,
remains only 3% (2). Although survival rates for childhood
medulloblastoma are better, long-term neurological deficits
secondary to radiation therapy remains a significant problem (3).
Therefore, therapeutic strategies that selectively induce apopto-
sis in brain tumors while sparing surrounding neural tissue could
offer significant clinical promise.
Apoptosis is a form of programmed cell death required for
proper embryonic development and tissue homeostasis. Aber-
rant signaling allows malignant cells to evade apoptosis, thus
fostering tumor progression (4). In the intrinsic pathway of
apoptosis, death-inducing signals converge upon the mitochon-
dria, causing release of cytochrome c. Cytosolic cytochrome c
binds to Apaf-1, leading to recruitment of procaspase-9 and
formation of the apoptosome. Apoptosome-mediated activation
of caspase-9 activates executioner caspase-3 and caspase-7,
which promote cell death (5).
Cytosolic cytochrome c is sufficient to induce apoptosis in
many dividing cells, including fibroblasts, HEK293, andHeLa (6,
7). In contrast, differentiated sympathetic neurons are highly
resistant to apoptosis induced by cytochrome c (8). This differ-
ential susceptibility to cytochrome c-induced death in cycling
cells and neurons led us to hypothesize that activating apoptosis
with cytochrome c might selectively induce death in dividing
brain tumor cells while sparing neurons in the brain parenchyma.
However, this idea was tempered by the fact that various tumors
have been shown to differ markedly in their sensitivity to
cytochrome c. Although ovarian cancers and melanomas appear
resistant to cytochrome c-induced apoptosis (9, 10), breast
cancers are hypersensitive to cytochrome c (11).
We show here that, despite the remarkable resistance of
mature neurons and brain tissues to cytochrome c, both high-
grade astrocytoma and medulloblastoma are susceptible to
cytochrome c-mediated apoptosis. Importantly, although nor-
mal brain exhibits nearly undetectable levels of Apaf-1, we
demonstrate that brain tumors express high levels of Apaf-1
through transcriptional induction of Apaf-1 mRNA. These re-
sults identify direct activation of the apoptosome as a potential
therapeutic strategy for brain tumors that would eliminate
cancer cells while sparing surrounding neural tissue.
Results
Multiple Types of Neurons Become Resistant to Cytochrome c upon
Maturation. We recently reported that decreased Apaf-1-
dependent apoptosome activity, which accompanies neuronal
differentiation, renders sympathetic neurons resistant to cyto-
chrome c-mediated apoptosis (8). To determine whether the
development of cytochrome c resistance is seen in other neurons,
including those in the CNS, we examined neurons from the
dorsal root ganglion (DRG), cerebellum, and cortex. Because
these neurons mature at different times, we chose two time
points for each neuronal type, corresponding to early and late
stages of differentiation. Sensory neurons from the DRG were
isolated from embryonic day 15 (E15) and postnatal day 2 (P2)
mice. Microinjection of cytochrome c into E15 DRG neurons
after 1 day in culture (E16 equivalent) induced extensive death
within 3 h. In contrast, P2 DRG neurons injected after 1 day in
culture (P3 equivalent) were remarkably resistant to cytochrome
c (Fig. 1A).
To examine the sensitivity of cerebellar granule neurons
(CGN) and cortical neurons to cytochrome c, we used a cell-free
assay, as the small size of these neurons is unsuitable for
microinjection. In this assay, addition of cytochrome c to cyto-
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solic lysates (extracts) prepared from either primary tissue or
cultured cells can recapitulate caspase-dependent apoptosis (6).
Although cytochrome c induced robust caspase activation in
extracts of P5 CGN maintained 1 day in culture (P6 equivalent),
no significant caspase activation was detected in extracts of P5
CGN maintained 14 days in culture (P19 equivalent) (Fig. 1B).
Next, we examined whether cortical extracts exhibited a similar
resistance to cytochrome c with maturation. Addition of cyto-
chrome c was sufficient to activate caspases in cortical extracts
from E16 but not P12 mice (Fig. 1C). Together, these results
show that our previous observations in sympathetic neurons, in
which cytochrome c sensitivity is dramatically decreased upon
maturation, can be generalized to multiple neuronal cell types,
including those of the CNS.
To determine whether the resistance to cytochrome c upon
neuronal maturation correlated with Apaf-1 down-regulation,
we examined components of the apoptotic machinery in early
and late stages of neuronal differentiation. Immunoblot analysis
confirmed that, in all neuronal cell types examined, Apaf-1 levels
were high in early-stage neurons but markedly decreased with
maturation (Fig. 1D).
Cytochrome c Induces Robust Caspase Activation in Brain Tumor Cells.
Unlike in neurons, in many dividing cells the introduction of
cytosolic cytochrome c induces apoptosis. This difference
prompted us to investigate whether brain tumors would be
sensitive to cytochrome c while surrounding neural tissue would
be resistant. We first confirmed that components of the apo-
ptotic machinery were present in extracts from neuroblastoma
(SH-SY5Y), medulloblastoma (UW228, D341MED, MCD1),
and glioblastoma (MGR3, MGR1, D54MG, D247MG, H392)
cell lines (Fig. 2A). Next, we found that cytochrome c elicited
robust caspase activation in all of the brain tumor cell line-
derived extracts, but not in extracts of mouse cortex or cerebel-
lum (Fig. 2B).
As an alternative to working with cultured cells, we examined
whether human brain tumor cells grown s.c. in immunocompro-
mised mice also exhibited cytochrome c sensitivity. Xenograft
extracts were prepared from human medulloblastoma
(D341MED), human glioma from adults (D54MG, U87MG)
and children (H2159MG, D456MG) and ependymoma (EP528,
EP612). Consistent with the cultured cell data, addition of
cytochrome c to the xenograft extracts elicited marked caspase
activation. In contrast, extract from adult human cortex did not
induce caspase activation upon cytochrome c addition (Fig. 2C).
Endogenous Mouse Models of High-Grade Astrocytoma and Medullo-
blastoma Demonstrate Selective Cytochrome c-Induced Caspase Ac-
tivation in Tumor Tissue. To extend relevance of these results to
brain tumor models where spontaneously forming lesions within
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Fig. 1. Cytochrome c is incapable of activating caspases and inducing
apoptosis in mature neurons. (A) E16 and P3 neurons from DRG were micro-
injected with 10 g/l cytochrome c and rhodamine dextran (for visualiza-
tion). Data shown are neuronal survival at times after injection and are
mean  SEM of three independent experiments. In corresponding images,
arrows indicate microinjected cells. (Magnification:400.) (B and C) Cytosolic
lysates from CGN (B) and whole cortex (CTX) (C) at early and late stages of
neuronal maturation were assessed for caspase activation after the addition
of 10 M cytochrome c. Caspase activation was monitored via cleavage of
DEVD-afc. Yeast cytochrome c, which cannot bind Apaf-1 (8), was added to
extracts as a negative control. (D) Immunoblotting shows protein levels of
Apaf-1, caspase-9, and caspase-3 in DRG, CGN, and whole cortex at early and
late stages of neuronal differentiation.
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Fig. 2. Brain cancer cells are hypersensitive to cytochrome c-induced apo-
ptosis. (A) Protein levels of Apaf-1, caspase-9, and caspase-3 were examined in
human brain tumor cell lines by immunoblotting. SY5Y, neuroblastoma;
UW228, D341MED, and MCD1, medulloblastoma; MGR3, MGR1, D54MG,
D247MG, and H392, glioblastoma. (B) Extracts from human brain tumor cell
lines or mouse neural tissue were supplemented with 8 M cytochrome c.
Caspase activation was monitored via cleavage of Ac-DEVD-pNA. Data shown
are mean  SEM of three independent experiments. mCtx, mouse cortex;
mCer, mouse cerebellum. (C) Extracts from human non-neoplastic temporal
cortex and xenograft tumors were assessed for their ability to activate
caspases as in B. U87MG and D54MG, adult glioma; H2159MG and D456MG,
pediatric glioma; D341MED, medulloblastoma; EP528 and EP612,
ependymoma.
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the brain more accurately mimic human disease, we examined
whether cytochrome c could induce caspase activation in tumors
from both high-grade astrocytoma and medulloblastoma mouse
models. These models enabled us to compare tumor tissue with
surrounding neural tissue from the same animal. In the high-
grade astrocytoma model, mice have been engineered to achieve
somatic pRb inactivation and constitutive K-rasG12D activation
with or without PTEN deletion, specifically in adult astrocytes.
Tumors from these mice have been histopathologically charac-
terized as predominantly anaplastic astrocytoma (WHO grade
III) or glioblastoma (WHOgrade IV) (Q.Z., C. R.Miller, C. Yin,
C. Y. Yang, E. Bullitt, K. D.McCarthy, T. Jacks, D. N. Louis, and
T.V.D., unpublished data). Extracts from these tumors exhibited
strong caspase activation upon addition of cytochrome c,
whereas extracts prepared from adjacent neural tissue did not
(Fig. 3A). Next, we examined the ability of cytochrome c to
activate caspases in tumors from patched heterozygous mice that
develop medulloblastoma (12, 13). Caspases were activated in
medulloblastoma extracts after cytochrome c addition, whereas
no caspase activation was detected in extracts of adjacent
cerebellar tissue (Fig. 3B). Consistent with apoptosome-
mediated apoptosis, caspase-9 processing was observed in both
high-grade astrocytoma and medulloblastoma extracts supple-
mented with cytochrome c, but not in extracts prepared from
adjacent neural tissue (Fig. 3C). These data illustrate the po-
tential of cytochrome c to activate caspases selectively in brain
tumors in vivo.
Apaf-1 Expression Levels Determine the Differential Sensitivity to
Cytochrome c in Normal and Malignant Brain Tissue. In considering
the molecular basis for the differential cytochrome c sensitivity
of brain tumor and normal brain tissue, we reflected on our
earlier observations that cytochrome c resistance in differenti-
ated sympathetic neurons was caused by low Apaf-1 levels (8).
Low Apaf-1 expression was also observed in mature cerebellar
and cortical neurons (Fig. 1D) (14). In contrast, Apaf-1 expres-
sion was clearly evident in the brain cancer cell lines (Fig. 2B).
Importantly, Apaf-1 immunoblotting revealed markedly higher
Apaf-1 protein levels in both high-grade astrocytoma and me-
dulloblastoma tumors compared with adjacent neural tissues
(Fig. 4A). A similar difference was observed in human high-
grade gliomas compared with normal human cortex (Fig. 4D).
To investigate whether differences in Apaf-1 expression were
responsible for the differential sensitivity to cytochrome c, we
added recombinant Apaf-1 protein to extracts prepared from
late-stage CGNs, adult mouse cortex and cerebellum. Although
no caspase activation was observed with cytochrome c alone, the
addition of Apaf-1 and cytochrome c was sufficient to induce
caspase activation (Fig. 4B). Likewise, human cortical extracts
showed caspase activation with cytochrome c and Apaf-1 but not
with cytochrome c alone (Fig. 4E).
We wanted to determine whether the low levels of Apaf-1 were
sufficient to activate caspases in the mature brain if caspase
inhibition by the inhibitor of apoptosis proteins (IAPs) was
relieved. Addition of Smac, an IAP inhibitor, to extract fromWT
adult mouse cortex did not promote increased caspase activation
(Fig. 4C). Additionally, extracts of XIAP/ and WT adult
mouse cortex displayed similar resistance to cytochrome c (and
similar sensitivity upon Apaf-1 addition) (Fig. 4C). These data
illustrate that the low levels of Apaf-1 in adult mouse cortex (Fig.
4C) and cerebellum (data not shown) could not induce caspase
activation even upon inactivation or removal of IAPs.
Levels of Apaf-1 in Normal and Malignant Brain Tissue Are Transcrip-
tionally Regulated. Having found that levels of Apaf-1 protein
underlie the observed sensitivity to cytochrome c, we examined
whether this difference could be traced back to transcriptional
regulation. Quantitative RT-PCR revealed that Apaf-1 mRNA
was significantly more abundant in medulloblastoma than in
adjacent cerebellum (Fig. 5A). Importantly, Apaf-1 mRNA
levels in isolated medulloblastoma cells were comparable with
developing P7 cerebellum, which is comprised of granule cell
precursors; levels in both were significantly higher than in
mature cerebellum (Fig. 5A).
We then investigated Apaf-1 mRNA abundance in human
astrocytomas by analyzing data from published gene profiling
studies available in the Oncomine Gene Profiling Database.
Analysis of data from Sun et al. (15) demonstrated a statistically
significant increase in Apaf-1 mRNA levels in glioblastoma
compared with brain from epilepsy patients (Fig. 5B). In two
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additional studies (16, 17), relative Apaf-1 mRNA expression
was increased in glioblastoma (grade IV astrocytoma) compared
with grade III astrocytoma (Fig. 5B). Similarly, a human tissue
dot blot revealed a marked increase in Apaf-1 protein expression
from a low-grade astrocytoma to a glioblastoma (Fig. 5C). These
data suggest not only that Apaf-1 expression is differentially
regulated in normal versus tumor cells, but also that Apaf-1
expression increases with increasing tumor grade.
To elucidate the mechanism of Apaf-1 mRNA up-regulation
in brain tumors, we examined the levels of E2F1 and p53, two
previously identified transcriptional activators of Apaf-1 (18–
20). Levels of E2F1, but not p53, were consistently up-regulated
in tumor tissues and low in adjacent brain tissues (Fig. 5D).
Additionally, many tumors, including two of the brain tumor
lines we analyzed (MGR1 and MCD1), have mutations in p53
(ref. 21 and Francis Ali-Osman, personal communication). We
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therefore focused on determining whether E2F1 was associated
with the Apaf-1 promoter in brain tumors. Indeed, ChIP assays
demonstrated that E2F1 specifically associates with the Apaf-1
promoter in mouse medulloblastoma tissue and the human
glioblastoma cell line MGR3 (Fig. 5E). In aggregate, the coor-
dinated up-regulation of E2F1 and Apaf-1 in brain tumor cells,
the previously reported ability of E2F1 to drive Apaf-1 tran-
scription, and the ability of E2F1 to bind Apaf-1 promoter in
brain tumors all suggest that E2F1 contributes to Apaf-1 expres-
sion in brain tumors.
Discussion
Low Apaf-1 Levels Offer Protection from Cytochrome c-Dependent
Apoptosis in Differentiated Neurons and Neural Tissue.Resistance to
cytochrome c-induced apoptosis in neuronally differentiated rat
pheochromocytoma PC12 cells and differentiated sympathetic
neurons has been reported (8). In this study, we show that this
striking development of resistance to cytochrome c during
maturation is seen in multiple types of neurons, including those
of the CNS. Specifically, we demonstrate this resistance in
isolated late-stage neurons (Fig. 1) and extracts from adult
mouse cortex and cerebellum (Fig. 2B) and human cortex
(Fig. 2C).
We have examined the mechanistic basis for this neuronal
resistance to cytochrome c-mediated apoptosis and identified a link
between Apaf-1 expression levels and the developmental state of a
neuron. As neurons mature they dramatically decrease their levels
of Apaf-1. Reconstitution with recombinant Apaf-1 protein in
late-stage neurons and mature neural tissue (Fig. 4 B and E)
restores sensitivity to cytochrome c-induced apoptosis, thus pro-
viding strong evidence that down-regulation of Apaf-1 is the critical
factor underlying the observed apoptotic resistance.
Similarly, other studies in rodent brain (14, 22) and mouse
retina (23) have reported that neuronal maturation leads to
inhibition of apoptosis, which parallels a decrease in Apaf-1
expression. We theorize that the reduction in Apaf-1 levels
accompanying neuronal maturation may be a way of restricting
unwanted apoptosis in differentiated neurons, in which long-
term survival is necessary. Thus, up-regulation of Apaf-1 is
predicted to be necessary and sufficient for these neurons to
undergo cytochrome c-mediated apoptosis under pathological
conditions. Indeed, during DNA damage-induced neuronal
death (18, 24) and after fluid percussion-induced traumatic brain
injury (14), Apaf-1 levels were markedly increased.
Brain Tumor Susceptibility to Cytochrome c-Induced Apoptosis. Al-
though inhibition of apoptosis is a hallmark of cancer, different
cancers use distinct mechanisms to serve this purpose. In some
instances, cancer cells evade apoptosis by preventing mitochon-
drial cytochrome c release in response to apoptotic stimuli.
Other tumors display resistance to cytoplasmic cytochrome c
because of defective apoptosome formation (25, 26). In contrast,
we have previously shown that breast cancers are actually
hypersensitive to cytochrome c-induced apoptosis relative to
normal mammary epithelial cells (11).
Given this unexpected phenomenon in breast cancer cells, we
decided to investigate the sensitivity of primary brain tumors to
cytochrome c-induced apoptosis. Using cultured human brain
tumor cells (Fig. 2B), human brain cancer-derived xenograft
tumors (Fig. 2C), and in vivo mouse models of high-grade
astrocytoma andmedulloblastoma (Fig. 3), we found that, unlike
their normal counterparts, brain tumors are susceptible to
cytochrome c-induced apoptosis. Our mouse model data con-
firm this differential sensitivity between tumor tissue and adja-
cent neural tissue despite common genetic alterations in both
tissues in the engineered mice. Although the sensitivity of breast
and brain cancers to cytochrome c is superficially similar, the
underlying mechanisms governing this sensitivity appear to be
entirely distinct. Specifically, breast cancer cytochrome c hyper-
sensitivity reflects overexpression of the apoptosome activator
PHAPI, without alterations in levels of core apoptosome com-
ponents (11). However, we report here that brain tumor sensi-
tivity to cytochrome c is controlled through elevation of Apaf-1
expression relative to the extremely low levels present in mature
neurons and neural tissue (Fig. 4).
Moreover, this difference in Apaf-1 is transcriptionally regu-
lated (Fig. 5A). Of note, Oncomine analysis of publicly available
microarray data suggests that Apaf-1 mRNA levels are not only
higher in glioblastoma relative to normal brain, but also that
Apaf-1 mRNA levels increase with increasing tumor grade (Fig.
5B). It may be that, because Apaf-1 transcription can be regu-
lated by E2F1, increased Apaf-1 levels are an inexorable con-
sequence of the increased E2F1 levels associated with (and in
part responsible for) increased proliferation in tumor cells.
According to this model, we would expect elevated Apaf-1 levels
in poorly differentiated, highly proliferative brain tumors, which
we did indeed observe in comparing glioblastoma (grade IV
astrocytoma) with well differentiated grade II astrocytoma (Fig.
5C). Furthermore, expression of E2F1 has recently been shown
to be sufficient to cause brain tumors in mice (27). Here, we show
that brain tumors harbor high levels of E2F1, whereas levels in
normal brain are quite low (Fig. 5D). Furthermore, our ChIP
studies suggest a physiological role for E2F1 in promoting Apaf-1
transcription in brain tumors (Fig. 5E).
Although Apaf-1 can be regulated at the transcriptional level,
it has been reported previously that Apaf-1 translation initiates
via an internal ribosomal entry segment (IRES) (28). One
known factor in IRES-mediated Apaf-1 translation, nPTB, is
expressed in neuronal cell lines (29, 30). Therefore, keeping
Apaf-1 protein levels low in mature neurons may critically
depend on keeping Apaf-1 mRNA levels low. It is attractive to
speculate that neurons are poised to translate Apaf-1 should the
message be produced, for example, under conditions of neuronal
damage where reinstatement of Apaf-1-dependent apoptosis
might be desirable.
Apoptosome Activation as a Therapeutic Strategy. In aggregate, our
data show that activating apoptosis with cytochrome c induces
caspase activation in brain tumors but not in mature neural
tissue. We have demonstrated that this differential sensitivity to
cytochrome c is caused by a transcriptionally regulated differ-
ence in Apaf-1 levels. Although apoptotic resistance upstream of
mitochondrial cytochrome c release likely renders brain tumors
refractory to standard chemotherapeutics, our results show that
they remain sensitive to apoptosis induced by cytochrome c.
Exploiting this vulnerability by directly activating the apopto-
some with peptides or small molecules that mimic cytochrome c
is therefore an attractive therapeutic approach for cancer cells
that maintain functionally active apoptosome components. Im-
portantly, our results from extracts of neural tissue, which are
comprised of both neurons and glia, suggest that, like mature
neurons, glia are also likely to be resistant to cytochrome c.
Therefore, we believe that the development of a cytochrome c
mimetic would be particularly beneficial in the context of brain
tumors where it would selectively induce apoptosis in tumor cells
while sparing adjacent brain tissue.
Because local delivery of a cytochrome c mimetic would be
necessary to avoid potential systemic side effects, wafer implant
technology would be one feasible approach. During brain tumor
excision, gel wafers embedded with chemotherapeutics are in-
serted into the space previously occupied by tumor, resulting in
slow release of drug precisely in the region of persisting malig-
nant cells (31). Ongoing studies are focused on the development
of a cytochrome c mimetic that could be delivered in such a
manner to eliminate brain tumor cells without harming sur-
rounding neural tissue.
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Materials and Methods
Cell Culture and Microinjection. Primary neurons from the DRG and the
cerebellum were cultured as described (32, 33). SH-SY5Y neuroblastoma cells
(gift from Daniel Sanchis, Universitat de Lleida, Lleida, Spain) were maintained
in a 1:1 mixture of DMEM and Ham’s F12 supplemented with 10% FBS.
Glioblastoma lines, MGR1 and MGR3 (gifts from Francis Ali-Osman, Duke
University), were maintained in low glucose DMEM supplemented with 10%
FBS. Medulloblastoma lines UW228 (gift from John Silber, University of Wash-
ington, Seattle) and MCD1 (gift from William Freed, National Institutes of
Health, Bethesda) were maintained in DMEM supplemented with nonessen-
tial amino acids, L-glutamine, and 10% FBS. Remaining glioblastoma and
medulloblastoma lines were obtained from the Duke University Preston Rob-
ert Tisch Brain Tumor Center and maintained in RPMI medium 1640 supple-
mented with 10% FBS. Sensory neurons from the DRG were microinjected by
using 10 g/l cytochrome c as described (8). The microinjection solution
contained 100 mM KCl, 10 mM KPi (pH 7.4), and 4 mg/ml rhodamine dextran
to mark injected cells. Cell viability was determined by counting rhodamine-
positive cells with intact, phase-bright cell bodies.
Extract Preparation. Cytosolic extracts from cultured neurons were prepared
as described (8). Brain tumor cell lines, xenograft tumors, and human cortical
tissues were harvested, washed with cold PBS, and pelleted. Pellets were
resuspended in hypotonic lysis buffer [20 mM Hepes (pH 7.5), 10 mM KCl, 1.5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 5 g/ml
leupeptin, and 5 g/ml aprotinin] with 250 mM sucrose, and incubated for 15
min on ice. Tissues were homogenized by using a 0.5-ml Bellco glass homog-
enizer and centrifuged for 30 min at 14,000 rpm (Eppendorf 5415C) at 4°C, and
the supernatant was preserved as extract. Extracts were quantitated by using
the Bradford method. Xenograft tumors, human cortical tissue, and high-
grade gliomas were provided by the Tisch Brain Tumor Center. Tissues were
diced on ice into 1-mm3 pieces, and extracts were prepared as above. Medul-
loblastoma tumor cells were isolated for RT-PCR as described (12).
Caspase Assays. Assays were performed as described (8, 11). In brief, extracts
were incubated with 10 M either mammalian or yeast cytochrome c and 1
mM dATP at 37°C for 30 min before addition of the fluorogenic substrate,
Ac-DEVD-afc (Biomol). Alternatively, extracts alone or with 8 M cytochrome
c were incubated as above before addition of the colorimetric substrate
Ac-DEVD-pNA (Biomol).
Immunoblotting. Antibodies used include: anti-caspase-9 [M0543 (MBL Inter-
national); 9504 (Cell Signaling)], anti-procaspase 3 (9665; Cell Signaling),
anti-Apaf-1(13F11 and 2E12; Alexis), anti-p53 (DO1; Santa Cruz), anti-E2F1
(C-20; Santa Cruz), anti--tubulin (T9026; Sigma), and anti--actin (A5316;
Sigma). Either Alexa Fluor secondary antibodies were used with the LI-Cor
Odyssey IR Imaging System or HRP-conjugated secondary antibodies (Pierce
Chemical) along with an ECL-Plus detection system (Amersham Biosciences).
Protein array of human astrocytomas was from the BioChain Institute
(A1235713-1).
Real-Time RT-PCR. RNA was isolated by using the small-scale RNAqueous Kit
and treated with DNase I (Ambion). For RT-PCR, first-strand cDNA was syn-
thesized with an oligo(dT) primer by adding300g of RNA with SuperScript
III Reverse Transciptase (Invitrogen). Real-time PCR was performed by using iQ
SYBR Green Supermix (BioRad), 10 M forward and reverse primers (se-
quences available on request), and 5 ng of cDNA. Real-time quantitation was
performed by using a BioRad iCycler iQ System. Data were normalized to
2-microglobulin, and fold change was determined by using the 2CT
method (34). For RT-PCR agarose gel analysis, reactions were performed as
above except with iQ Supermix.
OncomineMicroarray Data Analysis. Three independent gene profiling studies
(15–17) publicly available on the Oncomine Cancer Profiling Database (www.
oncomine.org) were used to investigate Apaf-1 mRNA levels. The resulting
data were analyzed as described by Turley et al. (35). Briefly, the mean Apaf-1
expression and the SD were calculated for each study. Differences in Apaf-1
expression between epileptic patient brain and glioblastoma were displayed
by using a standard box-and-whisker plot. For data from the other two studies
(16, 17), we calculated the standard difference in means of Apaf-1 mRNA
expression between grade III and grade IV astrocytomas by using the statistical
program Comprehensive Metaanalysis (Biostat).
ChIP Assay. ChIP was performed by using the EpiQuik Tissue Chromatin
Immunoprecipitation Kit (Epigentek P-2003). DNA was purified by using a
QIAquick PCR purification kit (Qiagen), and PCR was performed by using iQ
Supermix (BioRad). Approximately 2% of the input chromatin and 7% of the
ChIP samples were used as template in each case (primer sequences available
on request). Amplicons were visualized with ethidium bromide in 2.5%
agrarose gels.
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